Association between diabetes complications and leukocyte counts in Iranian patients

Journal of Inflammation Research

Volumn 5, Issue 1, 2012, Pages 7-11

  Moradi, Sedigheh ^a   Kerman, Scott Reza Jafarian ^a   Rohani, Farzaneh ^a   Salari, Fereshteh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes complications; Inflammation; Leukocytes

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ALBUMINURIA; ARTICLE; ASIAN; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; HUMAN; IRANIAN; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 84856771979     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S26917     Document Type: Article

References (33)

1. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34(Suppl 1):S11-S61.
2. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol. 2002;90(5A):27G-33G.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-1431.
4. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34(5):1164-1170.
5. Bunce C, Wormald R. Causes of blind certifications in England and Wales. Eye. 2008;22(7):905-911.
6. Avisar R, Friling R, Snir M, Avisar I, Weinberger D. Estimation of prevalence and incidence rates and causes of blindness in Israel, 1998-2003. Isr Med Assoc J. 2006;8(12):880-881.
7. Cusumano A, Garcia-Garcia G, Di Gioia C, et al. End-stage renal disease and its treatment in Latin America in the twenty-first century. Ren Fail. 2006;28(8):631-637.
8. Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009; 122(Suppl 1):S3-S14.
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
10. The diabetes control and complications trial research group: The effect of intensive treatment of diabetes on development and progression of long term complications in insulin dependent diabetes mellitus. N Eng J Med. 1993;329(14):997-986.
11. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-444.
12. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(24):115-126.
13. Weijenberg MP, Feskens EJ, Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Arterioscler Thromb Vasc Biol. 1996;16(4):499-503.
14. Tong PC, Lee KF, So WY, et al. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care. 2004;27(1):216-222.
15. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38(4):S100-S106.
16. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1(4):447-456.
17. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 1988;240(4858):1546-1548.
18. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 1989;170(4):1387-1407.
19. Andersen JU, Mauricio D, Karlsen AE, Mandrup-Poulsen T, Nielsen JH, Nerup J. Interleukin-1B-induced nitric oxide production from isolated rat islets is modulated by D-glucose and 3-isobutyl-1-methylxanthine. Eur J Endocrinol. 1996;134(2):251-259.
20. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62-S69.
21. Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications. 2003;17(3):120-127.
22. Kang ES, Kim HJ, Ahn CW, et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005;69(2):151-159.
23. Hanley AJ, Karter AJ, Festa A, et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51(8):2642-2647.
24. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53(5):1195-1200.
25. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53(8):2087-2094.
26. Bo M, Massaia M, Raspo S, et al. Predictive factors of in-hospital mortality in older patients admitted to a medical intensive care unit. J Am Geriatr Soc. 2003;51(4):529-533.
27. Chung FM, Tsai JC, Chang DM, Shin SJ, Lee YJ. Peripheral total and differential leukocyte count in diabetic nephropathy: the relationship of plasma leptin to leukocytosis. Diabetes Care. 2005;28(7):1710-1717.
28. Tsai JC, Sheu SH, Chiu HC, et al. Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2007;23(2):111-118.
29. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102(1):42-47.
30. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23(12):1835-1839.
31. Pécsvarády Z, Fisher TC, Darwin CH, et al. Decreased polymorphonuclear leukocyte deformability in NIDDM. Diabetes Care. 1994;17(1):57-63.
32. Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res. 2007;40(8):1037-1044.
33. Stegenga ME, Vander Crabben SN, Dessing MC, et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med. 2008;25(2):157-164.